Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU - MSN

European Commission Approves Pfizer's Hympavzi for Haemophilia A and B

The European Commission (EC) has approved Pfizer's Hympavzi (marstacimab) for routine prophylaxis of bleeding episodes in haemophilia A and B patients.
Hympavzi is the first anti-tissue factor pathway inhibitor approved in the EU for haemophilia A or B, administered via a pre-filled, auto-injector pen.

EU Approves Pfizer's Hympavzi for Hemophilia A and B

The European Commission has granted marketing authorization for Pfizer's Hympavzi (marstacimab) for hemophilia A and B patients aged 12 and older.
Hympavzi is a once-weekly prophylactic treatment to reduce bleeding episodes in patients without inhibitors to Factor VIII (FVIII) or Factor IX (FIX).

EU Approves Pfizer's Hympavzi for Severe Hemophilia A and B

The European Commission has granted marketing authorization for Hympavzi, a new treatment developed by Pfizer.
Hympavzi is indicated for severe hemophilia A or B in both adult and adolescent patients without inhibitors.

European Commission Approves Pfizer's HYMPAVZI for Hemophilia A and B

The European Commission has granted marketing authorization to Pfizer's HYMPAVZI (marstacimab) for treating hemophilia A and B based on Phase 3 trial results.
HYMPAVZI is the first once-weekly, subcutaneous treatment in the EU for severe hemophilia B and can be administered via a pre-filled, auto-injector pen.

EU Approves Pfizer's Hympavzi as First Weekly Subcutaneous Treatment for Severe Hemophilia B

The European Commission has approved Pfizer's Hympavzi, a once-weekly subcutaneous treatment, for severe hemophilia B in adults and adolescents without inhibitors.
Hympavzi is the first anti-TFPI antibody approved in Europe for hemophilia A or B without inhibitors, offering convenient at-home administration via autoinjector.

European Commission Approves Pfizer's Hympavzi for Hemophilia A and B

The European Commission has approved Pfizer's Hympavzi for routine prevention of bleeding episodes in hemophilia A and B patients aged 12 and older.
Hympavzi is the first once-weekly subcutaneous treatment in the EU for severe hemophilia B, offering a new administration route.

FDA Approves Pfizer's Hympavzi for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq), a once-weekly subcutaneous injection, for hemophilia A and B to prevent or reduce bleeding episodes.
Hympavzi is the first anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B, offering a new mechanism of action.

AstraZeneca gets FDA approval for PNH drug Voydeya - MSN

EC approves Daiichi Sankyo's Vanflyta for acute myeloid leukaemia - MSN

FDA Approves Pfizer's Hympavzi (Marstacimab) for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B.
Hympavzi is the first anti-tissue factor pathway inhibitor approved in the U.S. for hemophilia A or B, offering a novel mechanism of action.